ClinicalTrials.gg
CompletedNCT00165737Updated Apr 1, 2011

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

A Phase 3 interventional study of Donepezil Hydrochloride in Dementia, Vascular, sponsored by Eisai Inc.. Completed at 5 sites in United States. Open to participants aged 41 Years and older. Per ClinicalTrials.gov, last updated 2011-04-01.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
974
Allocation
Randomized
Ages
41 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 65 studies in Dementia, Vascular with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Dementia, Vascular · United States.

Enrollment
5th of 47
974 · median 100
Started
2003
the only one that year
Phase 3
5 of 65
none open now
Registered
3rd of 65
by date
Lead sponsor
2 of 65
Eisai Inc.

Among the 65 studies in Dementia, Vascular with a site in United States, this one is the 5th largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2003, is one of 5 in phase 3, and was the 3rd registered.

Dementia, Vascular

183 studies on the registry are indexed under Dementia, Vascular; 42 are open to participants now.

Browse Dementia, Vascular studies →

Open to participants now

16 of the 65 studies in Dementia, Vascular with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dementia, Vascular studies recruiting now, 25 (71%) set no upper age limit and 2 (6%) stop at 75 or younger; 4 take children under 18; 13 take healthy volunteers.

This study: 41 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Dementia, Vascular with a site in United States, or all of them as a file.
02

Study summary

Twenty-four week, prospective, randomized, double-blind, placebo-controlled, parallel-group study.

03

Conditions studied

  • Dementia, Vascular

Browse trials for

Keywords

  • Dementia cerebrovascular disease
04

Who can participate

Ages eligible
41 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Age range: Adult patients (>40 years old) 2 Possible or Probable Dementia associated with cerebrovascular disease as defined by NINDS-AIREN Criteria with dementia of greater than 3 months duration.
  1. Radiological evidence of cerebrovascular disease. 4. Sex distribution: Both men and women. Women of (\<1 year post menopausal) must be willing to practice effective and have a negative serum B-HCG at Screening. Pregnant and/or lactating females are excluded.
  1. Race and Health: Any generally healthy, ambulatory or ambulatory aided (i.e., walker, cane or wheelchair) outpatient. Vision and hearing (glasses, contact lens, and hearing aid permissible), speech, motor function and comprehension must be sufficient for compliance with all testing procedures.
  1. Patients with risk factors of hypertension and cardiac disease may be enrolled in the study, provided that hypertension is medication controlled (supine diastolic BP \< 95 mm Hg) and cardiac disease (e.g. angina pectoris, congestive heart failure, right bundle branch block, or arrhythmias) is stable on appropriate medication for 3 months prior to Screening. Peripheral vascular disease must have been stable for 3 months prior to Screening. No elective surgical procedures should be planned during the course of the study (e.g., vascular bypass procedures or coronary artery bypass surgery).
  1. Patients with risk factors of diabetes mellitus may be enrolled in the study, provided that the patient's disease is stable and that there have been no recent (within 3 months) admissions for diabetic ketoacidosis, hyperosmolar coma, or hypoglycemia. Patients with non-insulin-dependent diabetes may enroll in the study if controlled on diet or oral medications. All diabetic patients must have a concentration of \<=10% and a plasma glucose concentration of \<= 250 mg/dL.
  1. Patients with risk factors of stroke may be enrolled in the study, provided that the disease process has been stable or controlled on medication for greater than 3 months prior to Screening. Patients receiving anticoagulation with warfarin are eligible for inclusion in the study if the (INR) for prothrombin time is within the therapeutic range for prophylaxis (1.4-3.0) and the dose of warfarin is stable.

-- Patients with prosthetic heart valves, who require full anticoagulation, should have a stable (>= 3 months) INR in the range of 2.5-3.5.

  1. Patients who have taken a previously approved cholinesterase inhibitor (e.g., Aricept., Exelon., Reminyl., Cognex.) or memantine (Ebixa, Akinatol) are allowed provided that the medication was discontinued at least six (6) weeks prior to Screening.
  1. Patients with thyroid disease may be included in the study, provided they are euthyroid on treatment.
  1. Patient and study partner are willing to participate and have provided written prior to being exposed to any study-related procedures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
974 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety: physical examinations, ECG and clinical laboratory tests. Efficacy: Vascular-Alzheimer's Disease Assessment Scale-Cognitive subscale (V-ADAS-cog) and the Clinician's Interview-Based Impression of Change-Plus Version (CIBIC-Plus).

    Time frame: Parameters will be measured prior to, during and at the end of the study.

07

Study locations

5 sites
  • Central Arkansas Research (CARE)
    Hot Springs, Arkansas 71913, United States
  • Comprehensive Neuroscience
    St. Petersburg, Florida 33702, United States
  • St. Francis Medical Center
    Peoria, Illinois 61637, United States
  • Neurological Associate of Albany PC
    Albany, New York 12208, United States
  • University of Texas Mental Sciences Institute
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Aug 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 14, 2005
Start
Mar 2003
Primary completionActual
Aug 2005
CompletionActual
Jun 2006
Last update
Apr 1, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00165737
Lead sponsor
Eisai Inc.
First posted
Sep 14, 2005
Start date
Mar 2003
Primary completion
Aug 2005
Completion
Jun 2006
Last update
Apr 1, 2011

Study contacts

Holly Posner
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion